CNTA$26.86
Chart
Performance
Key Stats
AI CNTA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyCentessa Pharmaceuticals shows promising growth and a strong thematic alignment in the biotech sector, with solid, albeit mixed, technical indicators. Its fundamental performance, particularly in recent quarters, presents opportunities for investors seeking long-term growth.
Thematic
Centessa Pharmaceuticals is positioned in the growing clinical-stage pharmaceutical market, focusing on neurological disorders. Its innovative approach with ORX750 and other pipeline drugs aligns with increasing healthcare demands.
Fundamental
The company has a clean balance sheet with significant cash reserves, but currently shows negative EPS and no revenue, indicating it is in a pre-revenue stage. Recent performance suggests increasing operational expenses but limited revenue generation.
Technical
The stock shows a strong upward trend across multiple timeframes, with most moving averages indicating a buy signal. However, some oscillators are approaching overbought territory, suggesting a potential for a short-term pause.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Market Need | 75 |
| Drug Development Stage | 65 |
| Biotech Industry Growth | 70 |
| Regulatory Landscape | 55 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 20 |
| Growth | 30 |
| Balance Sheet Health | 90 |
| Cash Flow | 35 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 50 |
| Volume Confirmation | 70 |
| Support & Resistance | 75 |
| Overall Trend Strength | 85 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Cash Position
The company has a robust cash and cash equivalents position of $383.22 million, providing significant financial flexibility.
Significant Positive Momentum
The stock has shown strong performance over various periods, including 23.42% in the last month and 64.22% in the last year, indicating positive investor sentiment and potential for continued growth.
Bearish Points (8)
Negative Revenue and Net Income
The company has reported zero revenue for 2024 and 2022, and significant net losses across reported periods, indicating a lack of current profitability and potential business model challenges.
High Price-to-Sales Ratio
The Price-to-Sales (PS) ratio is exceptionally high (e.g., 305.1 in 2023), which is unsustainable for a company with minimal or no revenue, suggesting a significant overvaluation.
Calendar
August 2025
12
Next Earnings Date
H: $-0.30
A: $-0.34
L: $-0.37
Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Seasonals
Price Target
31.50 USD
The 39 analysts offering 1 year price forecasts for CNTA have a max estimate of 38.00 and a min estimate of 26.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
As the largest online travel agency (OTA) in China, Trip.com Group (formerly Ctrip) is a primary platform for flight, hotel, and package bookings, directly serving millions of Chinese tourists domestically and internationally.
Weight: 97
CTGF is the largest duty-free operator in China, holding a dominant market position. Its performance is directly tied to inbound, outbound, and domestic tourism spending, especially for luxury goods.
Weight: 96
Meituan is a leading e-commerce platform for local services in China, with a massive presence in hotel booking, dining, and local leisure activities, making it indispensable for domestic tourists.
Weight: 95
Huazhu Group is one of the largest multi-brand hotel groups in China, operating well-known brands like Hanting, Jill, and Grand Mercure. Its extensive network directly serves the vast domestic tourism market.